Here are the DEF 14A proxy statements from Organogenesis Holdings Inc. (ORGO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ORGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORGO filings page.
Organogenesis Holdings Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 15, 2026 at 11:00 a.m. Eastern. Investors will elect nine common directors, cast an advisory say-on-pay vote on 2025 executive compensation, and ratify RSM US LLP as independent auditor for 2026.
As of April 23, 2026, 128,674,548 shares of Common Stock and 130,000 shares of Convertible Preferred Stock, convertible into 38,470,359 Common shares, were entitled to vote together. Preferred holders can elect one board member while they hold at least 5% of the as-converted Common. Executive pay blends base salary, annual cash bonuses tied mainly to net revenue and Adjusted EBITDA, and long-term equity including stock options, RSUs and new performance share awards, which in 2025 vested at the maximum level for the first tranche based on revenue growth.